
PAPR-I




Powered Purified Air Respirator - Isolated (PAPR-I)
Background studies
Use of PAPR's as related to FFP2 and FFP3 type one-time-use masks.
The design and use of masks has come under much greater study due to their use being recommended to help counter risks of spreading COVID - 19, principally via exhaled respiratory aerosol droplets. Several studies have shown that the FFP2 and FFP3 type of mask while being effective in reducing laboratory verified virus infections, they are not recommended for use over extended periods due to build up and re-breathing of the exhalate trapped within the mask.
Oxygen values have been shown to drop from 21% to 16% (OSHA states 19.5% is the minimum level of oxygen for a working environment) and there can be a 100 fold increase in carbon dioxide from 0.04% or 400 ppm to around 4.0% or 40,000 ppm.
ASHRAE and OSHA carbon dioxide acceptable level standard: 1,000 ppm
General drowsiness: 1,000 - 2,500 ppm
Adverse health effects may be expected: 2,500 - 5,000 ppm
Maximum allowed concentration within a 8 hour working period: 5,000 - 10,000 ppm
Maximum allowed concentration within a 15 minute working period: 30,000 ppm
The FFP2 and FFP3 type of mask also reduces the normal air flow and the user has to work harder to breath at the normal rate. There is a standard measure for breathing resistance and OSHA sets a maximum of 30 H2O units back pressure for a standard flow rate. Generally any mask over 15 H2O is noticeably more difficult to breath through.
Due to the nose and mouth being covered, a significant reduction in both aural and visual communication is experienced which impacts operational effectiveness.
From a social/psychological stand point, the adoption of face masks for health care workers reduces their ability to provide adequate communication, care and reassurance for their patients.
The use of PAPR systems has seen a big increase despite the systems not being appropriate or designed for use in viral aerosol control applications or isolation wards. Typically a PAPR is designed for use in areas where the air is contaminated by various hazardous elements such as dust, smoke, spray paint etc. and no filtering of the users exhalate is provide for.
Normally in a medical setting a surgical mask is worn inside the PAPR hood. However the surgical mask provides little to no added protection to patients when using a normal PAPR on an isolation ward as there is no built-in filtering for the users exhalate and aerosol dispersion will be increased.
For Covid-19 testing facilities for example the personal protective equipment for operatives could be improved as the one piece protective overall hood does not fit over current PAPR equipment and the hood is an essential feature of such protective equipment.
Generally available PAPR’s are made to be durable in an industrial setting and are correspondingly expensive and as such have to be shared by users and cleaned between each use.
Usually in two main parts with an air compressor and battery worn on the waist, and a fabric hood with a semi-rigid visor. The two components are connected by a large diameter flexible hose and typically these systems can weigh between 1-2 kilograms. Effective cleaning of this equipment is time consuming and generally shortcuts are taken.
​
​
​
bioshield PAPR-I solutions.
Methods of construction to achieve a lightweight transparent device that mitigates all of the above deficiencies in current FFP2 and FFP3 type masks and available PAPR systems.
The PAPR-I is a disposable, ultra-light full face transparent mask, using a flexible foil material, that also houses a small self-contained powered air compressor at the base of the mask. The compressor draws air into the mask through inlet filter areas at the base. Notably the re-usable compressor is inside the mask and is not contaminated by the environment. The compressor essentially provides a laminar airflow over the transparent foil within the mask from the base. The laminar air stream directly entrains the exhalate from the user which is then immediately carried through secondary filter areas to the external atmosphere at lower velocity.
The system is therefore two-way isolating as exhalate is filtered hence PAPR-I.
The PAPR-I can be worn for extended periods as there is no restrictive element to normal breathing rates, no build up of contamination from naturally excreted toxins, moisture and carbon dioxide and no reduction in oxygen content from exhalate, and can be used on isolation wards without an additional mask.
The full face transparent foil allows personal interaction and facial expression which is of profound importance when dealing with children and adults with heightened levels of anxiety. The lightweight transparent foil surround gives minimal reduction in volume or audio quality of the users voice.
The transparent thin foil shield wraps closely around the face and to each side with a 100% vapour/particle/fluid barrier. The shape of the foil shield has been laboratory developed using visible vapour techniques.
We have used thin wall 3D printed designs as shown here in the research and development pictures to optimise the required characteristics. The foil has a semi-circular tubular form, and forms a part conical tunnel close to the face, with a relatively small gap between the foil and the face. The internal air compressor supplies a laminar air stream directly to the inside bottom surface of the transparent foil and keeps the surface fog and moisture free.
Using laminar flow techniques greatly increases the effectiveness of the compressor and prolongs battery life. The transparent foil is also anti-mist coated on both sides to prevent fogging in cold environments. No aerosol particulates are released from the mask as the exhalate is filtered.
The bioshield PAPR-I is not designed for multiple re-use as it has lightweight characteristics and designed to be disposable. The design form allows the device to be blow moulded as a pair of masks, which are easily separated and allows high volume production at low cost equivalent to a 1 litre PET blow moulded bottle. However, the device can be reused multiple times and the inlet filter element can be replaced with custom inserts for the required application.
The small independent air compressor and power supply are retained after use and are simply removed and placed into a fresh PAPR-I. The independent air compressor and power supply are conveniently enclosed in a transparent clam shell that allows the battery status display to be monitored. The clam shell can be opened for access and recharging the battery.
The airflow of the compressor is not a limiting factor for intermittent increased breathing rates as the filter arrangement has a high transmission rate with a low pressure differential, and an ultralight flap valve arrangement ensures continuos through flow.
The battery power supply is sufficient for 24 hours continual use. The battery can be charged in situ via a standard 5V USB-C lead, and the battery can be exchanged to allow charging of more than one battery.
The transparent clam shell is also disposable and allows the compressor to be shared with other users. Variations in clam shell design and the use of custom filters can be made available.

Patent Application


Lamina Flow
Demonstration
The transparent thin foil shield wraps closely around the face and to each side with a 100% vapour/particle/fluid barrier over the eyes, nose and mouth.
The shape of the foil shield has been laboratory developed using visible vapour techniques. The foil has a semi-circular tubular form, and forms a part conical tunnel close to the face, with a relatively small gap between the foil and the face. The internal air compressor supplies a laminar air stream directly to the inside bottom surface of the transparent foil and keeps the surface fog and moisture free. Using laminar flow techniques greatly increases the effectiveness of the compressor and prolongs battery life. The transparent foil is also anti-mist coated on both sides to prevent fogging in cold environments. No aerosol particulates are released from the mask as the exhalate is filtered.

Preventative health care
- Why awareness of zeta potential is important -
Rouleaux formation can be a light transient phenomenon which is usually reversible with grounding for example. However a significant reduction in zeta potential can lead to rouleaux with a sticky formation resistant to breakup. This is extremely important for individuals to know, so that remedial action can be taken - and progress can be monitored. Due to perhaps an underlying pathology, rouleaux formation can become dense over a short period of time, indicating a loss of zeta potential and an increase in blood viscosity, leading to reduced blood flow and various cardiovascular complications.​​ Because tissue perfusion is inversely proportional to blood viscosity, the reduction in zeta potential and the development of rouleaux formation is of great concern and should be addressed as widely as possible. Bi-annual screening of high risk groups to increase awareness and responsibility within the population would be beneficial.
​
Implication of reduced zeta potential and dense Rouleaux Formation -
-
Underlying pathology that requires further investigation: Elevated triglycerides can lead to changes in plasma proteins, reduced zeta potential and rouleaux formation, chronic kidney disease can cause changes in plasma proteins, including albumin, leading to rouleaux formation.
-
Rouleaux formation creates a hyper-coagulable state and may impair oxygen delivery, contributing to tissue ischemia. If the red blood cell aggregation response is indeed systemic, it may have wide reaching multi-systemic effects, including the development or exacerbation of hypertension.
-
Morbidity is determined by the patient's underlying health status. Ischemic heart disease, diabetes, prethrombotic states, cancer, peripheral vascular disease, retinopathy, and cerebrovascular insufficiency are among the risk factors that will increase the morbidity associated with the reduction in zeta potential and development of rouleaux.
Detection/Screening-
Significant advantage comparison - monitoring rouleaux/zeta potential against monitoring with blood pressure.
​​​
​
​
The table lists experimental data which needs to be clinically validated
Other than Micro Lab there is no at-home/point-of-care screening for zeta potential/rouleaux currently available.
Because zeta potential has been a time consuming metric to measure in a path lab - it has not been possible to use as a widespread diagnostic tool. Measurement of zeta potential is usually analysed through access to a research pathology lab - Zeta potential analysers such as Electrophoresis and ELS.​
Given the association between the reduction in zeta potential and rouleaux formation - with hypertension and cardiovascular risk, a smartphone based blood test such as Micro Lab can be extremely beneficial for a wide range of individuals at risk or with pre-existing conditions.
​
Facilities that could benefit -​
-
Pharmacies
-
Healthcare clinics
-
Doctors surgeries
-
Hospitals
-
Care homes
​
​
Personal Health Care -
-
For those interested in personal health and fitness, the red blood cells shape and dynamics indicate changes in vitality, and an increase in zeta potential can be seen during training, and the impact of dietary regimes/supplements and hydration can be monitored for best effect.
​
Those at risk -
-
High-risk individuals: Those with a family history of cardiovascular disease, hypertension, diabetes, or kidney disease.
-
Adults: Individuals typically over 40 years old, zeta potential decreases with age, and those who do not take regular exercise and have a poor diet.
-
Obese or overweight individuals: Those with a body mass index (BMI) of 30 or higher, as obesity is a significant risk factor for cardiovascular disease.
-
Individuals at risk of kidney disease or have high triglyceride levels.
Cost saving - CVD Risk assessment - Nation Wide screening for zeta potential
​
All adults would benefit from an annual zeta potential pin prick screening, but particularly so with 50–60% of adults over 40 in higher risk groups - where a bi-annual test would be more appropriate.
​
There is the potential to save an astonishing $0.5 trillion annually in the USA alone based on projected figures of reduced incidence of CDV by 50% due to screening and suggesting improved lifestyles to maintain or even improve zeta potential in the population through appropriate protocols. Sunshine, exercise, good food and grounding are all important elements - seaside holidays are good for your health!
​
The introduction of insurance funded bi-annual zeta potential screening of high risk group of 50M members in the USA would cost around $2 billion based on the cost of infrastructure, with a 250x return on investment. Even with a 1% reduction in disease produces a net saving of $8 billion. This hypothetical example makes a compelling case for zeta potential screening as a cost-effective preventive healthcare strategy.
​Market Potential - Health and Fitness -
​The global market for home blood testing devices, which includes finger-prick tests used by health and fitness consumers, was estimated at approximately USD $20 billion in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 10.3% from 2025 to 2035, reaching an estimated USD 53,3 billion by 2035.
With awareness of the importance of zeta potential testing and the ability for competitive athletes to also increase their zeta potential, Micro Lab at an affordable price could be a market leader.
​
Potential Future Developments -
​​
-
Artificial intelligence-powered analysis: Leveraging AI to analyse each of the test results and provide personalised recommendations for lifestyle changes and medical interventions.
-
Telemedicine integration: Enabling remote monitoring and consultation with healthcare professionals to facilitate timely interventions.
-
Point-of-care testing: Integrating the device at all levels allowing for real-time analysis and decision-making.
​
Revenue Streams-
-
Device sales: Revenue generated from the sale of the Micro Lab
-
Subscription services: Offering subscription-based services for data analysis, personalised recommendations, and telemedicine consultations.
-
Partnerships and collaborations: Pharmacies, Healthcare providers and insurance companies, to promote the awareness of zeta potential and the benefits of bi-annual screening.
Challenges and Considerations-
-
Regulatory hurdles: Navigating regulatory approvals and certifications to ensure the device's safe and effective use.
-
Public awareness and adoption: Educating the public about the device's benefits and encouraging adoption.
-
Data security and privacy: Ensuring the secure storage and transmission of sensitive health data. The sample slide can be returned to the patient to prevent DNA being harvested without consent.
Reduced Mortality and Morbidity -
-
The device could lead to a reduction in CVD-related deaths, a saving over time of literally millions of lives.
-
By preventing or delaying CVD events, individuals could gain years of life, contributing to a healthier and more productive population.
Public Health Benefits -
-
Increased health literacy: Educating the public about cardiovascular risk factors and the benefits of early detection of low zeta potential could improve health awareness and empower individuals to take control of their health.
-
Internet examples of high and low zeta potential video blogs could become a thing. Micro fluidics are a fascinating window into human biology.
-
Reduced healthcare costs: By reducing the number of hospitalisations, complications, and healthcare services required to manage CVD, the device could lead to significant cost savings and improve accessibility.
​
​Reference links to Published articles -
​
1.https://www.intechopen.com/chapters/72171
Zeta Potential as a Diagnostic Tool to Determine the Angina Risk
​
2.https://newsi8.com/zeta-potential-what-it-is-and-why-it-matters-to-health/
Zeta Potential, What it Is and Why It Matters to Health
3.https://www.liebertpub.com/doi/10.1089/acm.2011.0820
Earthing (Grounding) the Human Body Reduces Blood Viscosity—a Major Factor in Cardiovascular Disease
​
​
Conclusion
​
Blood pressure monitoring has been the mainstay for early diagnosis and for assessing cardiovascular risk and guiding therapeutic interventions. It is clear zeta potential falls earlier and further than blood pressure rises as a result of rouleaux, highlighting it's potential as an early predictive marker. Not until the advent of Micro Lab has this predictive marker been possible to be usefully employed for regular monitoring of blood health. The underlying causes for reduced zeta potential are complex but it has been shown that grounding, lifestyle and dietary changes have a profound effect on improving zeta potential and blood health, and with appropriate management can help mitigate the adverse effects of rouleaux and increased blood viscosity on cardiovascular health.
​
Micro Lab
A Pathology Lab in your pocket.
Real-time results - anywhere - anytime
​​




